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Introduction
 made up of physiological lipids or synthetic
 SLN  : 50‐1000 nm
 first introduced by Muller et al in 1991 
 Therapeutic , cosmetic and dermal, diagnostic 
application
 Last few years as colloidal drug carriers
 Several advantage ,minimize disadvantage
3Solid lipid nanoparticle-May 2016
History:
4
 Solid lipid used for several in form of pellet in 
peroral administration
 Speicer  and coworker (1980) : solid lipid 
microparticle with high speed mixer
 Muller et al (1991):submicron size of  solid lipid 
with High pressure homogenization(SLN)






























 controlled drug release
 less toxic
 Protecting the labile and sensitive drugs from  
degradation
 ease of scale‐up 
 Low cost  
 physical stability
 lipophilic and hydrophilic compounds can be
delivered by SLN
 biodegradable     
 different administration routes
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Challenge(1):
 Entrapment  of water soluble drugs
Polymeric Lipid Hybrid Nanoparticles (PLN)
 Avoidance of Reticulo Endothelial System(RES)
coating with PEG,POLOXAMINE
` Stealth particle`
 Controlled release of drug: 
Nanostructured Lipid Carriers (NLC)
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GENERAL INGREDIENTS(2):
 Solid lipid     
triglycerides, partial glycerids
fatty acids, steroids ,waxes
physiological lipids decreases the danger 
of acute and chronic toxicity.
 Emulsifier
used to stabilize the lipid dispersion
prevent particle agglomeration
 water
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Lipids and emulsifiers used  for 
SLN
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W. Mehnert, K. Ma¨der / Advanced Drug Delivery Reviews 47 (2001) 165 –196
SLN Production(3):
 SLN can be produced by various techniques:
 High pressure homogenization
 High shear homogenization and ultrasound
 Microemulsion based SLN preparations
 Supercritical Fluid technology 
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High pressure 
homogenization:
 Powerful technique 
 pushes the liquid with high pressure (100-2000 
bar) through a narrow gap ranging a few microns.
 The fluid accelerates to a very high viscosity of 
over 1000 km/h.
 Very high shear stress and cavitation forces 
disrupt the particles down to submicron range. 
 5% - 40%: lipid content 





 high speed homogenization
 Initially techniques
 advantage :equipment used is commonly available
 problems: broader size 
metal contaminations
physical instability 
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Microemulsion based SLN 
preparation
 dilution of 
microemulsions
 The hot microemulsion 
is dispersed in cold 
water (2-3°C) under 
stirring.
 Lipid content are 
lower compare with 
the HPH
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Supercritical Fluid technology(4):
 novel technique




 particles obtained as a dry powder
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advantage disadvantage
Hot  homogenization Smaller particle •temperature induce 
drug degradation 
• complexity of the 
crystallization




•Equipment used is 
very common





•Broader particle size 














 Autoclave: heat resistant drug
 Filtration: particle size below 200nm 
 gamma irradiation
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Drug release from SLN(5)
 drug in the outer 
shell and on the 
particle surface: 
released in the form 
of a burst
 The drug 
incorporated into 
the particle core 
:released in a 
prolonged way. 
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Drug release from SLN
 Higher temperatures and higher surfactant 
concentrations: increase the burst
 SLN can be produced surfactant free or using 
surfactants which are not able
to solubilizethe drug: avoid 
or minimize the burst




 particle size and zeta potential
 degree of crystallintity and lipid modification
 coexistence of additional colloidal structures
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Particle size:
 Photon correlation 
spectroscopy (PCS)
 dynamic light scattering
 detects size range of 3nm 
to 3μm 
 good tool to characterize 
nano-particles
 fluctuation of the 
intensity of the scattered 
light which is caused by 
particle movement
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Particle size:
 laser diffraction (LD) diffraction  angle on the 
particle radius 
Detect size range  of 100 
nm to 180 μm.
 detection of larger 
microparticle
 recommended to use PCS 
and LD simultaneously
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Morphological structure:
 Atomic force 
microscopy (AFM) 
 Obtains image quickly
 Observation of in situ
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Zeta potential :
zeta potential analyzer or zetameter.               
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Measurement of crystallinity, 
lipid  modification:
 related with drug 
incorporation and 
release rates
 Differential scanning 
calorimetry (DSC) 
 X-ray scattering
 Infrared and Raman 
spectroscopy
27Solid lipid nanoparticle-May 2016
coexistence of additional 
colloidal structures
 nuclear magnetic 
resonance (NMR) 
 electron spin resonance 
(ESR) 
 investigating dynamic 
phenomena













 potential new adjuvant for vaccines
 gene therapy
 central nervous system diseases 
 SLNs as cosmeceuticals
 potential agriculture application
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Drug loader(7-8):
 Many different drugs 
incorporated in SLN
 important point: 
loading capacity
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solubility of drug in 
melted lipid
 miscibility of drug 
melt and lipid melt
 chemical and physical 







 Side effect 
 Drug resistance
 enhanced  permeability 
and retention(EPR)
 Active tumor targeting
 Encapsulation of 
chemotherapeutic drug 
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SLN in tubercular 
chemotherapy:
 Anti  tubercular drug(ATD)
 Oral administration
 Detected in plasma 8 days
 Drug Concentration Above or Minimum inhibitory 
concentration(MIC90)
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 Higher concentration in 
serum
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SLN in cancer chemotherapy:
 first in‐vivo studies
 Yang et al in 1999
 Camptothecin is an anticancer
 camptothecin‐SLN(CA‐SLN)
 increased accumulation of CA‐SLN in brain,
heart and RES organs
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 Oyewumi et al
 PEG and folate coated SLN of gadolinium
 Increased cellular uptake and retention in cancer 
cell
 Bondi et al
 prepared NLC of anticancer drug temozolamide
 increase in the effect on human hepatocellular 
carcinoma cell line
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37https://www.google.com
new adjuvant for vaccines(10):
 Adjuvant are used in vaccination
 enhance the immune response.
 Freund's complete adjuvant (FCA) and Freund's 
incomplete adjuvant (FIA) 
 SLN:   degraded more slowly            
lasting exposure to the immune system
good tolerability by the body.
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gene therapy(11):
 good specificity to target cell 
 higher efficacy for transfection of genetic material
 Viral vectors unwanted immune response
 non viral transfection  like dendrimers
peptide
cationic lipids
polymers and liposome 
low in‐vivo effectiveness
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gene therapy:
•first in‐vivo study
•Gasco et al evaluated the 
transfection capacity 




•Protein expression  for at 
least one week.
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central nervous system(4):
 inability of drugs to pass blood brain barrier 
(BBB)
 SLN: transport of  BBB and tissue distribution 
increase
 Fundaro et al, 2000:doxorubicin loaded stealth 
and non-stealth SLN
 stealth nanoparticles  in blood at higher 
concentrations than non-stealth SLN after 24 h 






 Particle size: No problem
peroral or transdermal  administration
and i.m. or s.c. injection
parenteral administration:
pyrogens must be checked
Particle size distribution: embolism
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In vivo fate:
 (a) administration route
 (b) interactions of the SLN with the biological 
surroundings: 
distribution processes:
adsorption of biological material
desorption of The microclimate of SLN component 
enzymatic processes:
lipases and esterases            
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